216 related articles for article (PubMed ID: 16773847)
1. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
Richardson P
Oncology (Williston Park); 2006 May; 20(6):633-8. PubMed ID: 16773847
[No Abstract] [Full Text] [Related]
2. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
3. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
4. [Multiple myeloma -- therapy].
Jung W; Zettl F; Schroers R
Dtsch Med Wochenschr; 2005 Feb; 130(6):283-6; quiz 287-90. PubMed ID: 15692903
[No Abstract] [Full Text] [Related]
5. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
Mellstedt H; Gimsing P; Waage A
Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535
[No Abstract] [Full Text] [Related]
7. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
8. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
[No Abstract] [Full Text] [Related]
9. Bortezomib-induced Sweet syndrome.
Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
[No Abstract] [Full Text] [Related]
10. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
Pitini V; Arrigo C; Altavilla G; Naro C
Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
[No Abstract] [Full Text] [Related]
11. Hyperlipidemia in a myeloma patient after bortezomib treatment.
Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
[No Abstract] [Full Text] [Related]
12. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S
Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
[No Abstract] [Full Text] [Related]
14. Bortezomib (velcade) for multiple myeloma.
Med Lett Drugs Ther; 2003 Jul; 45(1161):57-8. PubMed ID: 12865865
[No Abstract] [Full Text] [Related]
15. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib for myeloma -- much ado about something.
Dispenzieri A
N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
[No Abstract] [Full Text] [Related]
17. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
[TBL] [Abstract][Full Text] [Related]
18. Expanding role of bortezomib in multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J
Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
[TBL] [Abstract][Full Text] [Related]
19. Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
Varettoni M; Vassallo C; Borroni G; Mangiacavalli S; Zappasodi P; Rosso R; Lazzarino M; Corso A
Ann Hematol; 2007 Apr; 86(4):301-2. PubMed ID: 17131123
[No Abstract] [Full Text] [Related]
20. Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Hattori N; Adachi D; Nakashima H; Saito B; Nakamaki T; Tomoyasu S
Leuk Res; 2009 Apr; 33(4):574-7. PubMed ID: 18838167
[No Abstract] [Full Text] [Related]
[Next] [New Search]